PubMed Health⌕ Search

PubMed · 12744297

Lansoprazole overutilization: methods for step-down therapy.

Abstract

OBJECTIVE: To identify the documented indications for long-term therapy with lansoprazole 30 mg twice daily at the Veterans Affairs Pittsburgh Healthcare System, assess compliance with appropriate use criteria, evaluate patients eligible for step-down therapy, and recommend appropriate step-down therapy in order to improve patient care, decrease overprescribing, and reduce medication costs. STUDY DESIGN: Prospective intervention. METHODS: The records of all patients with prescriptions for lansoprazole 30 mg twice daily as of June 2000 were reviewed. Patients were interviewed to assess medication compliance and symptom control and to provide education on lifestyle modifications. Interventions with the providers were completed to encourage step-down therapy in appropriate patients. RESULTS: Two hundred forty-eight patients with active prescriptions for twice-daily lansoprazole were reviewed. Of these patients, 66% (n = 163) did not have an indication compliant with the medical center's guidelines for use of lansoprazole 30 mg twice daily. Of these, 88% (n = 143) had no documented attempt at step-down therapy and 49% (n = 80) had no documented gastrointestinal workup. Interventions for step-down therapy were recommended for 48% (n = 120) of the 248 patients. Forty-six percent (n = 60) of recommendations were accepted, resulting in a cost savings of dollars 85000 per year. CONCLUSIONS: A high rate of clinician noncompliance with the guidelines for appropriate use of lansoprazole 30 mg twice daily was found. These prescribing patterns resulted in significant cost concerns. Our review and interventions led to step-down therapy for almost half of the patients receiving twice-daily lansoprazole. This review of patient records and intervention with primary care providers resulted in cost reduction and offered an opportunity to educate patients on beneficial lifestyle modifications.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Cynthia J Pohland, Stephanie A Scavnicky, Steve S Lasky, Chester B Good. 2003. Lansoprazole overutilization: methods for step-down therapy.. https://pubmed.ncbi.nlm.nih.gov/12744297/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Sequential treatment for Helicobacter pylori does not share the risk factors of triple therapy failure.

BACKGROUND: Predicting factors for the outcome of conventional Helicobacter pylori triple therapy have been identified. Of these, the presence of the CagA gene is a strong predictor of successful treatment. Our preliminary data show that this factor becomes irrelevant when sequential therapy is used. AIM: To identify predicting factors for the outcome of H. pylori eradication using two therapeutic schemes (triple and sequential) of equal duration (10 days). METHODS: Ninety-six patients with H. pylori infection were randomly assigned to receive one of the following therapeutic schemes: group A: rabeprazole (20 mg b.d.) plus amoxicillin (1 g b.d.) for 5 days, followed by rabeprazole (20 mg b.d.) plus tinidazole (500 mg b.d.) and clarithromycin (500 mg b.d.) for a further 5 days; group B: rabeprazole (20 mg b.d.) plus amoxicillin (1 g b.d.) and clarithromycin (500 mg b.d.) for 10 days. Age, sex, smoking, endoscopic and histological findings, and CagA and VacA status were considered as candidates for a model of multivariate analysis which used therapeutic outcome as the dependent variable. CagA and VacA status were assessed by polymerase chain reaction on DNA isolated from gastric antral specimens. RESULTS: The sequential scheme was significantly more effective than prolonged triple therapy (P < 0.05). Smoking (P < 0.001) and the absence of the CagA gene (P < 0.05) were significantly associated with the failure of triple therapy, but the effectiveness of sequential treatment was not predicted by these factors. CONCLUSION: Our data suggest that sequential therapy is not affected by bacterial and host factors which have, until now, predicted the outcome of conventional eradication treatments.

2-Pyridinylmethylsulfinylbenzimidazoles↗

Double-blind, randomized controlled study to assess the effects of lansoprazole 30 mg and lansoprazole 15 mg on 24-h oesophageal and intragastric pH in Chinese subjects with gastro-oesophageal reflux disease.

BACKGROUND: Previous studies have suggested that the acid secretory capacity of the Chinese population is lower than that of the Western population. AIM: To compare the effect of lansoprazole 30 mg and 15 mg once daily on the 24-h oesophageal and intragastric pH profiles in Chinese patients with gastro-oesophageal reflux disease. METHODS: Forty-four patients (male to female ratio, 27 : 17; mean age, 53 years; 55% with oesophagitis) with gastro-oesophageal reflux disease were randomized to receive lansoprazole 30 mg or 15 mg once daily for 4 weeks. Measurement of the 24-h oesophageal and intragastric pH, gastro-oesophageal reflux disease symptoms and quality of life was performed at baseline and during the last week of each dosing period. RESULTS: Lansoprazole 30 mg maintained an intragastric pH > 4 for 10.5 h vs. 9.6 h for lansoprazole 15 mg (P = 0.44). The percentage total time at oesophageal pH < 4 was similar for lansoprazole 30 mg and 15 mg (2.0% vs. 2.3%, P = 0.30). The proportion of patients with complete cure of heartburn and acid regurgitation and the quality of life assessment were similar for lansoprazole 30 mg and 15 mg. Both dosages of lansoprazole were well tolerated and the compliance was 100% in both groups. CONCLUSION: Lansoprazole dosages of 30 mg and 15 mg once daily provide a satisfactory decrease for oesophageal acid exposure and are equally effective for the treatment of gastro-oesophageal reflux disease in the Chinese population.

2-Pyridinylmethylsulfinylbenzimidazoles↗

The acidity index: a simple approach to the measurement of gastric acidity.

BACKGROUND: The percentage of time intragastric pH < 4 is a major parameter in evaluating the efficiency of acid-suppressive therapies. This parameter is easy to calculate, but does not identify the actual pH level. Recent studies have recommended the use of the integrated intragastric acidity as a more refined method of assessing intragastric acid control. AIM: To describe a new parameter, the acidity index, based on the logarithmic aspect of pH calculation, which may overcome the limitations of the percentage of time intragastric pH < 4 and the integrated intragastric acidity. METHODS: The acidity index was calculated by obtaining the sum of 1000 x % time pH < 1, 100 x % time pH < 2 and >or= 1, 10 x % time pH < 3 and >or= 2 and % time pH < 4 and >or= 3. The total percentage of time pH < 4 and the integrated intragastric acidity were calculated based on previous descriptions. The correlations between these parameters were analysed. RESULTS: The mean +/- s.d. values were 60% +/- 22% for the percentage of time pH < 4, 172 +/- 178 for the acidity index and 1114 +/- 1176 mmol/L.h for the integrated intragastric acidity. Both the integrated intragastric acidity (r = 0.63) and acidity index (r = 0.70) showed only fair correlation with the percentage of time pH < 4. In contrast, there was a strong positive correlation (r = 0.93) between the acidity index and integrated intragastric acidity. CONCLUSION: The acidity index is easy to calculate, allows a more accurate assessment of the intragastric acidity than does the percentage of time pH < 4, and is comparable with the more complicated integrated gastric acidity in assessing intragastric pH control.

2-Pyridinylmethylsulfinylbenzimidazoles↗